Trials / Not Yet Recruiting
Not Yet RecruitingNCT07455045
A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)
An Open-Label, Multicenter, Phase I Study of FZ-AD005 Antibody-Drug Conjugate in Patients With Recurrent/Refractory High-Grade Glioma (HGG)
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
An Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with HGG, especially in DMG and other Recurrent HGG.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FZ-AD005 | Every 21 days for 1 cycle. Subjects will receive an intravenous infusion of FZ-AD005 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study. |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2027-12-01
- Completion
- 2028-06-01
- First posted
- 2026-03-06
- Last updated
- 2026-03-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07455045. Inclusion in this directory is not an endorsement.